Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Breast Neoplasms"" wg kryterium: Temat


Tytuł :
Understanding breast cancer survivors' financial burden and distress after financial assistance.
Autorzy :
Semin JN; College of Public Health, University of Nebraska Medical Center, 984355 Medical Center, Omaha, NE, 68198-4355, USA. .
Palm D; College of Public Health, University of Nebraska Medical Center, 984355 Medical Center, Omaha, NE, 68198-4355, USA.
Smith LM; College of Public Health, University of Nebraska Medical Center, 984355 Medical Center, Omaha, NE, 68198-4355, USA.
Ruttle S; Visiting Nurse Association, 12565 West Center Road, Suite 100, Omaha, NE, USA.
Pokaż więcej
Źródło :
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2020 Sep; Vol. 28 (9), pp. 4241-4248. Date of Electronic Publication: 2020 Jan 03.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Springer International Country of Publication: Germany NLM ID: 9302957 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1433-7339 (Electronic) Linking ISSN: 09414355 NLM ISO Abbreviation: Support Care Cancer Subsets: MEDLINE
MeSH Terms :
Breast Neoplasms/*economics
Breast Neoplasms/*psychology
Adult ; Aged ; Breast Neoplasms, Male/economics ; Breast Neoplasms, Male/psychology ; Cancer Survivors/psychology ; Cross-Sectional Studies ; Emotions ; Female ; Financing, Personal ; Humans ; Male ; Middle Aged ; Quality of Life ; Socioeconomic Factors ; Surveys and Questionnaires ; United States
Czasopismo naukowe
Tytuł :
[New European approvals: Alpelisib for HRpos/HER2neg metastatic breast cancer with PIK3CA mutation].
Transliterated Title :
Nouvelles AMMs au niveau européen : alpélisib – cancer du sein RH+/HER2− métastatique avec mutation PIK3CA.
Autorzy :
Corbaux P; Institut de cancérologie des hospices civils de Lyon, université Claude-Bernard Lyon 1, centre hospitalier Lyon sud, faculté de médecine Lyon-Sud, département d'oncologie médicale, 165, chemin du Grand-Revoyet, 69310 Pierre-Bénite, France. Electronic address: .
Sabatier R; Institut Paoli-Calmettes, Centre de recherche en cancérologie de Marseille, laboratoire d'oncologie prédictive, département d'oncologie médicale, Inserm UMR1068, CNRS UMR7258, Aix-Marseille Université, 13009 Marseille, France.
Pokaż więcej
Źródło :
Bulletin du cancer [Bull Cancer] 2020 Oct; Vol. 107 (10), pp. 959-960. Date of Electronic Publication: 2020 Sep 22.
Typ publikacji :
Letter
Journal Info :
Publisher: Elsevier Country of Publication: France NLM ID: 0072416 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1769-6917 (Electronic) Linking ISSN: 00074551 NLM ISO Abbreviation: Bull Cancer Subsets: MEDLINE
MeSH Terms :
Estrogens*
Progesterone*
Breast Neoplasms/*drug therapy
Carcinoma, Ductal, Breast/*secondary
Class I Phosphatidylinositol 3-Kinases/*analysis
Neoplasm Proteins/*analysis
Neoplasms, Hormone-Dependent/*drug therapy
Receptor, ErbB-2/*analysis
Receptors, Estrogen/*analysis
Receptors, Progesterone/*analysis
Thiazoles/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Breast Neoplasms/chemistry ; Breast Neoplasms, Male/chemistry ; Breast Neoplasms, Male/drug therapy ; Carcinoma, Ductal, Breast/chemistry ; Carcinoma, Ductal, Breast/drug therapy ; Class I Phosphatidylinositol 3-Kinases/antagonists & inhibitors ; Clinical Trials as Topic ; Drug Approval ; Drug Resistance, Neoplasm ; Female ; Fulvestrant/administration & dosage ; Humans ; Male ; Multicenter Studies as Topic ; Neoplasm Proteins/antagonists & inhibitors ; Neoplasms, Hormone-Dependent/chemistry ; Thiazoles/administration & dosage
Opinia redakcyjna
Tytuł :
GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer.
Autorzy :
Wu Q; Structural Genomics Consortium, University of Toronto, Toronto, ON, M5G 1L7, Canada.; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, M5G 2M9, ON, Canada.
Ba-Alawi W; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, M5G 2M9, ON, Canada.
Deblois G; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.
Cruickshank J; The Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, Toronto, ON, M5G 2M9, Canada.
Duan S; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.
Lima-Fernandes E; Structural Genomics Consortium, University of Toronto, Toronto, ON, M5G 1L7, Canada.; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.
Haight J; The Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, Toronto, ON, M5G 2M9, Canada.
Tonekaboni SAM; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, M5G 2M9, ON, Canada.
Fortier AM; Goodman Cancer Research Centre, McGill University, Montreal, QC, H3A 1A3, Canada.
Kuasne H; Goodman Cancer Research Centre, McGill University, Montreal, QC, H3A 1A3, Canada.
McKee TD; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.; Princess Margaret Cancer Centre, STTARR Innovation Facility, Toronto, ON, Canada.
Mahmoud H; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, M5G 2M9, ON, Canada.; Faculty of Computer and Informatics, Benha University, Benha, Egypt.
Kushida M; Developmental and Stem Cell Biology Program and Arthur and Sonia Labatt Brain tumor Research Centre, The Hospital for Sick Children, Toronto, ON, M5G 0A4, Canada.
Cameron S; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, M5G 2M9, ON, Canada.
Dogan-Artun N; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, M5G 2M9, ON, Canada.
Chen W; Structural Genomics Consortium, University of Toronto, Toronto, ON, M5G 1L7, Canada.
Nie Y; Structural Genomics Consortium, University of Toronto, Toronto, ON, M5G 1L7, Canada.; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, M5G 2M9, ON, Canada.
Zhang LX; Structural Genomics Consortium, University of Toronto, Toronto, ON, M5G 1L7, Canada.
Vellanki RN; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.
Zhou S; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, M5G 2M9, ON, Canada.
Prinos P; Structural Genomics Consortium, University of Toronto, Toronto, ON, M5G 1L7, Canada.
Wouters BG; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, M5G 2M9, ON, Canada.
Dirks PB; Developmental and Stem Cell Biology Program and Arthur and Sonia Labatt Brain tumor Research Centre, The Hospital for Sick Children, Toronto, ON, M5G 0A4, Canada.; Division of Neurosurgery, University of Toronto, Toronto, ON, M5S 1A8, Canada.; Departments of Molecular Genetics and Surgery, University of Toronto, Toronto, ON, M5S1A8, Canada.
Done SJ; The Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, Toronto, ON, M5G 2M9, Canada.
Park M; Goodman Cancer Research Centre, McGill University, Montreal, QC, H3A 1A3, Canada.
Cescon DW; The Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, Toronto, ON, M5G 2M9, Canada.
Haibe-Kains B; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, M5G 2M9, ON, Canada.; Department of Computer Science, University of Toronto, Toronto, M5T 3A1, ON, Canada.; Ontario Institue for Cancer Research, Toronto, M5G 2M9, ON, Canada.; Vector Institute for Artificial Intelligence, Toronto, ON, Canada.
Lupien M; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada. .; Department of Medical Biophysics, University of Toronto, Toronto, M5G 2M9, ON, Canada. .; Ontario Institue for Cancer Research, Toronto, M5G 2M9, ON, Canada. .
Arrowsmith CH; Structural Genomics Consortium, University of Toronto, Toronto, ON, M5G 1L7, Canada. .; Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 1L7, ON, Canada. .; Department of Medical Biophysics, University of Toronto, Toronto, M5G 2M9, ON, Canada. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2020 Aug 21; Vol. 11 (1), pp. 4205. Date of Electronic Publication: 2020 Aug 21.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
Journal Info :
Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
MeSH Terms :
Glucose Transporter Type 1/*antagonists & inhibitors
Glucose Transporter Type 1/*metabolism
Retinoblastoma Binding Proteins/*metabolism
Triple Negative Breast Neoplasms/*metabolism
Ubiquitin-Protein Ligases/*metabolism
Animals ; Apoptosis/drug effects ; Biomarkers, Tumor ; Breast Neoplasms/metabolism ; Cell Cycle ; Cell Line, Tumor ; Cell Proliferation ; Female ; Gene Expression Regulation, Neoplastic/drug effects ; Glucose Transporter Type 1/genetics ; Humans ; Mice ; Oxidative Phosphorylation ; Proteomics ; Pyrazoles/pharmacology ; Pyridines/pharmacology ; Quinolines ; RNA, Messenger/metabolism ; Triple Negative Breast Neoplasms/genetics ; Ubiquitin-Protein Ligases/genetics
Czasopismo naukowe
Tytuł :
Is Multifocal Regression a Risk Factor for Ipsilateral Breast Tumor Recurrence in the Modern Era After Neoadjuvant Chemotherapy and Breast Conservation Therapy?
Autorzy :
Ling DC; Department of Radiation Oncology, Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Sutera PA; Department of Radiation Oncology, Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Iarrobino NA; Department of Radiation Oncology, Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Diego EJ; Division of Surgical Oncology, Department of Surgery, Magee-Women's Hospital, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Soran A; Division of Surgical Oncology, Department of Surgery, Magee-Women's Hospital, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Johnson RR; Division of Surgical Oncology, Department of Surgery, Magee-Women's Hospital, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Bhargava R; Department of Pathology, Magee-Women's Hospital, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Champ CE; Department of Radiation Oncology, Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Beriwal S; Department of Radiation Oncology, Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. Electronic address: .
Pokaż więcej
Źródło :
International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2019 Jul 15; Vol. 104 (4), pp. 869-876. Date of Electronic Publication: 2019 Mar 15.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Elsevier, Inc Country of Publication: United States NLM ID: 7603616 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-355X (Electronic) Linking ISSN: 03603016 NLM ISO Abbreviation: Int. J. Radiat. Oncol. Biol. Phys. Subsets: MEDLINE
MeSH Terms :
Mastectomy, Segmental*
Neoplasm Recurrence, Local*/pathology
Unilateral Breast Neoplasms*/etiology
Unilateral Breast Neoplasms*/pathology
Breast Neoplasms/*pathology
Breast Neoplasms/*therapy
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Breast Neoplasms/chemistry ; Breast Neoplasms/mortality ; Chemotherapy, Adjuvant ; Female ; Humans ; Middle Aged ; Multivariate Analysis ; Phenotype ; Receptor, ErbB-2 ; Receptors, Estrogen ; Receptors, Progesterone ; Retrospective Studies ; Risk Factors ; Treatment Outcome ; Triple Negative Breast Neoplasms/chemistry ; Triple Negative Breast Neoplasms/pathology ; Triple Negative Breast Neoplasms/therapy
Czasopismo naukowe
Tytuł :
Factors associated with genetic testing in a cohort of breast cancer survivors.
Autorzy :
Blaes AH; University of Minnesota, Minneapolis, Minnesota.
Jewett PI; University of Minnesota, Minneapolis, Minnesota.
McKay K; University of Minnesota, Minneapolis, Minnesota.
Riley D; University of Iowa, Iowa City, Iowa.
Jatoi I; University of Texas Health Science Center, San Antonio, Texas.
Trentham-Dietz A; Department of Population Health Sciences and Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin.
Chrischilles E; University of Iowa, Iowa City, Iowa.
Klemp JR; University of Kansas Medical Center, Kansas City, Kansas.
Pokaż więcej
Źródło :
The breast journal [Breast J] 2019 Nov; Vol. 25 (6), pp. 1241-1244. Date of Electronic Publication: 2019 Jul 03.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
Journal Info :
Publisher: Blackwell Science Country of Publication: United States NLM ID: 9505539 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1524-4741 (Electronic) Linking ISSN: 1075122X NLM ISO Abbreviation: Breast J Subsets: MEDLINE
MeSH Terms :
Breast Neoplasms*/genetics
Breast Neoplasms*/therapy
Cancer Survivors*/psychology
Cancer Survivors*/statistics & numerical data
Genetic Testing/*statistics & numerical data
Procedures and Techniques Utilization/*statistics & numerical data
Age Factors ; Causality ; Cross-Sectional Studies ; Female ; Health Services Accessibility ; Humans ; Middle Aged ; Socioeconomic Factors ; Triple Negative Breast Neoplasms/genetics ; Triple Negative Breast Neoplasms/therapy ; United States
Czasopismo naukowe
Tytuł :
Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy.
Autorzy :
Hamy AS; Residual Tumor & Response to Treatment Laboratory, RT2Lab, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France.; Department of Medical Oncology, Institut Curie, Saint-Cloud, France.
Darrigues L; Department of Surgery, Faculté de Médecine Descartes, Université Paris, Institut Curie, Paris, France.
Laas E; Department of Surgery, Faculté de Médecine Descartes, Université Paris, Institut Curie, Paris, France.
De Croze D; Department of Tumor Biology, Institut Curie, Saint-Cloud, France.
Topciu L; Department of Tumor Biology, Institut Curie, Paris, France.
Lam GT; Department of Surgery, Faculté de Médecine Descartes, Université Paris, Institut Curie, Paris, France.; Department of Gynecology and Obstetrics, Geneva University Hospitals, Geneva, Switzerland.
Evrevin C; Department of Medical Oncology, Institut Curie, Saint-Cloud, France.
Rozette S; Department of Medical Oncology, Institut Curie, Saint-Cloud, France.
Laot L; Department of Surgery, Faculté de Médecine Descartes, Université Paris, Institut Curie, Paris, France.
Lerebours F; Department of Medical Oncology, Institut Curie, Saint-Cloud, France.
Pierga JY; Department of Medical Oncology, Institut Curie, Saint-Cloud, France.; Department of Surgery, Faculté de Médecine Descartes, Université Paris, Institut Curie, Paris, France.
Osdoit M; Department of Surgery, Faculté de Médecine Descartes, Université Paris, Institut Curie, Paris, France.
Faron M; Department of biostatistics and epidemiology, INSERM 1018 CESP Oncostat team, Gustave Roussy Cancer Campus, Villejuif, France.
Feron JG; Department of Surgery, Faculté de Médecine Descartes, Université Paris, Institut Curie, Paris, France.
Laé M; Department of Tumor Biology, Institut Curie, Paris, France.
Reyal F; Department of Medical Oncology, Institut Curie, Saint-Cloud, France.; Department of Surgery, Faculté de Médecine Descartes, Université Paris, Institut Curie, Paris, France.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 Jun 24; Vol. 15 (6), pp. e0234191. Date of Electronic Publication: 2020 Jun 24 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Validation Study
Journal Info :
Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS ONE Subsets: MEDLINE
MeSH Terms :
Breast Neoplasms/*drug therapy
Breast Neoplasms/*mortality
Breast Neoplasms/*pathology
Adult ; Aged ; Aged, 80 and over ; Breast Neoplasms/metabolism ; Female ; Humans ; Middle Aged ; Neoplasm Recurrence, Local/pathology ; Neoplasm, Residual ; Prognosis ; Receptor, ErbB-2/metabolism ; Retrospective Studies ; Survival Analysis ; Triple Negative Breast Neoplasms/drug therapy
Czasopismo naukowe
Tytuł :
Tor Vergata University-Hospital in the Beginning of COVID-19-Era: Experience and Recommendation for Breast Cancer Patients.
Autorzy :
Buonomo OC; Breast Unit - Department of Surgical Science, Policlinico Tor Vergata University, Rome, Italy.
Materazzo M; Breast Unit - Department of Surgical Science, Policlinico Tor Vergata University, Rome, Italy.
Pellicciaro M; Breast Unit - Department of Surgical Science, Policlinico Tor Vergata University, Rome, Italy.
Caspi J; Breast Unit - Department of Surgical Science, Policlinico Tor Vergata University, Rome, Italy.
Piccione E; Section of Gynecology-Department of Surgical Science, Policlinico Tor Vergata University, Rome, Italy.
Vanni G; Breast Unit - Department of Surgical Science, Policlinico Tor Vergata University, Rome, Italy .
Pokaż więcej
Źródło :
In vivo (Athens, Greece) [In Vivo] 2020 Jun; Vol. 34 (3 Suppl), pp. 1661-1665.
Typ publikacji :
Journal Article; Practice Guideline
Journal Info :
Publisher: Dr. J.G. Delinassios Country of Publication: Greece NLM ID: 8806809 Publication Model: Print Cited Medium: Internet ISSN: 1791-7549 (Electronic) Linking ISSN: 0258851X NLM ISO Abbreviation: In Vivo Subsets: MEDLINE
MeSH Terms :
Coronavirus Infections*/epidemiology
Coronavirus Infections*/prevention & control
Coronavirus Infections*/psychology
Hospitals, University*
Hospitals, Urban*
Pandemics*/prevention & control
Pneumonia, Viral*/epidemiology
Pneumonia, Viral*/prevention & control
Pneumonia, Viral*/psychology
Breast Neoplasms/*diagnostic imaging
Breast Neoplasms/*therapy
Elective Surgical Procedures/*psychology
Mastectomy/*psychology
Treatment Refusal/*psychology
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Breast Neoplasms/psychology ; Breast Neoplasms/surgery ; Carcinoma/diagnostic imaging ; Carcinoma/psychology ; Carcinoma/surgery ; Carcinoma/therapy ; Carcinoma, Intraductal, Noninfiltrating/diagnostic imaging ; Carcinoma, Intraductal, Noninfiltrating/psychology ; Carcinoma, Intraductal, Noninfiltrating/surgery ; Combined Modality Therapy ; Delayed Diagnosis ; Disease Management ; Early Detection of Cancer ; Estrogens ; Female ; Humans ; Mammography ; Mass Screening ; Neoadjuvant Therapy ; Neoplasms, Hormone-Dependent/diagnostic imaging ; Neoplasms, Hormone-Dependent/psychology ; Neoplasms, Hormone-Dependent/surgery ; Neoplasms, Hormone-Dependent/therapy ; Rome ; Triple Negative Breast Neoplasms/diagnostic imaging ; Triple Negative Breast Neoplasms/psychology ; Triple Negative Breast Neoplasms/surgery ; Triple Negative Breast Neoplasms/therapy
SCR Disease Name :
COVID-19
Czasopismo naukowe
Tytuł :
Opposing Functions of BRD4 Isoforms in Breast Cancer.
Autorzy :
Wu SY; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Lee CF; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Lai HT; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Yu CT; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Lee JE; Adipocyte Biology and Gene Regulation Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Zuo H; Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Tsai SY; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Tsai MJ; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Ge K; Adipocyte Biology and Gene Regulation Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Wan Y; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Chiang CM; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: .
Pokaż więcej
Źródło :
Molecular cell [Mol Cell] 2020 Jun 18; Vol. 78 (6), pp. 1114-1132.e10. Date of Electronic Publication: 2020 May 23.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
Journal Info :
Publisher: Cell Press Country of Publication: United States NLM ID: 9802571 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-4164 (Electronic) Linking ISSN: 10972765 NLM ISO Abbreviation: Mol Cell Subsets: MEDLINE
MeSH Terms :
Breast Neoplasms/*metabolism
Cell Cycle Proteins/*metabolism
Cell Cycle Proteins/*physiology
Transcription Factors/*metabolism
Transcription Factors/*physiology
Animals ; Breast Neoplasms/genetics ; Cell Line, Tumor ; Cell Movement ; Cell Proliferation ; Female ; Gene Expression Regulation, Neoplastic/genetics ; Genes, Homeobox ; Homeodomain Proteins/metabolism ; Humans ; Mice ; Neoplasm Invasiveness ; Nuclear Proteins/metabolism ; Protein Isoforms/metabolism ; Proteins/antagonists & inhibitors ; Proteins/metabolism ; Transcription, Genetic/genetics ; Triple Negative Breast Neoplasms/genetics
Czasopismo naukowe
Tytuł :
Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses.
Autorzy :
Zhang H; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health (NIH), Department of Health and Human Services, Bethesda, MD, USA.; Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Ahearn TU; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health (NIH), Department of Health and Human Services, Bethesda, MD, USA.
Lecarpentier J; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
Barnes D; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
Beesley J; Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Qi G; Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Jiang X; Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
O'Mara TA; Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Zhao N; Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Bolla MK; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Dunning AM; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
Dennis J; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Wang Q; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Ful ZA; Clalit National Cancer Control Center, Carmel Medical Center and Technion Faculty of Medicine, Haifa, Israel.
Aittomäki K; Department of Clinical Genetics, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
Andrulis IL; Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
Anton-Culver H; Department of Epidemiology, Genetic Epidemiology Research Institute, University of California, Irvine, Irvine, CA, USA.
Arndt V; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Aronson KJ; Department of Public Health Sciences and Cancer Research Institute, Queen's University, Kingston, Ontario, Canada.
Arun BK; Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Auer PL; Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Zilber School of Public Health, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.
Azzollini J; Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy.
Barrowdale D; Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
Becher H; Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Beckmann MW; Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Behrens S; Division of Cancer Epidemiology, DKFZ, Heidelberg, Germany.
Benitez J; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Valencia, Spain.
Bermisheva M; Institute of Biochemistry and Genetics, Ufa Federal Research Centre of the Russian Academy of Sciences, Ufa, Russia.
Bialkowska K; Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Blanco A; Molecular Medicine Unit, Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain.; Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago, Servicio Galego de Saude (SERGAS), Santiago de Compostela, Spain.; CIBERER, Santiago de Compostela, Spain.
Blomqvist C; Department of Oncology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.; Department of Oncology, Örebro University Hospital, Örebro, Sweden.
Bogdanova NV; N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus.; Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.; Department of Radiation Oncology, Hannover Medical School, Hannover, Germany.
Bojesen SE; Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.; Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Bonanni B; Division of Cancer Prevention and Genetics, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
Bondavalli D; Division of Cancer Prevention and Genetics, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
Borg A; Department of Oncology, Lund University and Skåne University Hospital, Lund, Sweden.
Brauch H; Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.; iFIT Cluster of Excellence, University of Tübingen, Tübingen, Germany.; German Cancer Consortium (DKTK), DKFZ, Heidelberg, Germany.
Brenner H; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.; German Cancer Consortium (DKTK), DKFZ, Heidelberg, Germany.; Division of Preventive Oncology, DKFZ and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Briceno I; Bioscience Department, Faculty of Medicine, Universidad de la Sabana, Chia, Colombia.
Broeks A; Division of Molecular Pathology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Brucker SY; Department of Women's Health, University of Tübingen, Tübingen, Germany.
Brüning T; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Ruhr University Bochum, Bochum, Germany.
Burwinkel B; Molecular Epidemiology Group (C080), DKFZ, Heidelberg, Germany.; Molecular Biology of Breast Cancer, University Women's Clinic Heidelberg, University of Heidelberg, Heidelberg, Germany.
Buys SS; Department of Medicine, Huntsman Cancer Institute, Salt Lake City, UT, USA.
Byers H; Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester NIHR Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
Caldés T; Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Caligo MA; Section of Molecular Genetics, Department of Laboratory Medicine, University Hospital of Pisa, Pisa, Italy.
Calvello M; Division of Cancer Prevention and Genetics, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
Campa D; Division of Cancer Epidemiology, DKFZ, Heidelberg, Germany.; Department of Biology, University of Pisa, Pisa, Italy.
Castelao JE; Oncology and Genetics Unit, Instituto de Investigacion Sanitaria Galicia Sur (IISGS), Xerencia de Xestion Integrada de Vigo-SERGAS, Vigo, Spain.
Chang-Claude J; Division of Cancer Epidemiology, DKFZ, Heidelberg, Germany.; Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Chanock SJ; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health (NIH), Department of Health and Human Services, Bethesda, MD, USA.
Christiaens M; Leuven Multidisciplinary Breast Center, Department of Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
Christiansen H; Department of Radiation Oncology, Hannover Medical School, Hannover, Germany.
Chung WK; Departments of Pediatrics and Medicine, Columbia University, New York, NY, USA.
Claes KBM; Centre for Medical Genetics, Ghent University, Ghent, Belgium.
Clarke CL; Westmead Institute for Medical Research, University of Sydney, Sydney, New South Wales, Australia.
Cornelissen S; Division of Molecular Pathology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Couch FJ; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Cox A; Sheffield Institute for Nucleic Acids (SInFoNiA), Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
Cross SS; Academic Unit of Pathology, Department of Neuroscience, University of Sheffield, Sheffield, UK.
Czene K; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Daly MB; Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, USA.
Devilee P; Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands.
Diez O; Oncogenetics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Domchek SM; Department of Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Dörk T; Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
Dwek M; Department of Biomedical Sciences, Faculty of Science and Technology, University of Westminster, London, UK.
Eccles DM; Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK.
Ekici AB; Institute of Human Genetics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center ER-EMN, Erlangen, Germany.
Evans DG; Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester NIHR Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.; Division of Evolution and Genomic Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
Fasching PA; Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany.; David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
Figueroa J; Usher Institute of Population Health Sciences and Informatics, University of Edinburgh Medical School, Edinburgh, UK.
Foretova L; Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
Fostira F; Molecular Diagnostics Laboratory, INRASTES, National Centre for Scientific Research 'Demokritos', Athens, Greece.
Friedman E; The Susanne Levy Gertner Oncogenetics Unit, Chaim Sheba Medical Center, Ramat Gan, Israel.
Frost D; Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
Gago-Dominguez M; Genomic Medicine Group, Galician Foundation of Genomic Medicine, IDIS, Complejo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain.; Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Gapstur SM; Behavioral and Epidemiology Research Group, American Cancer Society, Atlanta, GA, USA.
Garber J; Cancer Risk and Prevention Clinic, Dana-Farber Cancer Institute, Boston, MA, USA.
García-Sáenz JA; Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Gaudet MM; Behavioral and Epidemiology Research Group, American Cancer Society, Atlanta, GA, USA.
Gayther SA; Center for Bioinformatics and Functional Genomics and the Cedars-Sinai Genomics Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Giles GG; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia.
Godwin AK; Department of Pathology and Laboratory Medicine, Kansas University Medical Center, Kansas City, KS, USA.
Goldberg MS; Department of Medicine, McGill University, Montréal, Québec, Canada.; Division of Clinical Epidemiology, Royal Victoria Hospital, McGill University, Montréal, Québec, Canada.; Breast Cancer Research Unit, Cancer Research Institute, University Malaya Medical Centre, Kuala Lumpur, Malaysia.
Goldgar DE; Department of Dermatology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA.
González-Neira A; Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Greene MH; Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Gronwald J; Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Guénel P; Cancer and Environment Group, Center for Research in Epidemiology and Population Health (CESP), INSERM, University Paris-Sud, University of Paris-Saclay, Paris, France.
Häberle L; Department of Gynaecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center ER-EMN, Erlangen, Germany.
Hahnen E; Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Haiman CA; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Hake CR; Waukesha Memorial Hospital Pro Health Care, Waukesha, WI, USA.
Hall P; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.; Department of Oncology, Södersjukhuset, Stockholm, Sweden.
Hamann U; Molecular Genetics of Breast Cancer, DKFZ, Heidelberg, Germany.
Harkness EF; Division of Informatics, Imaging and Data Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.; Nightingale Breast Screening Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
Heemskerk-Gerritsen BAM; Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Hillemanns P; Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
Hogervorst FBL; Family Cancer Clinic, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Holleczek B; Saarland Cancer Registry, Saarbrücken, Germany.
Hollestelle A; Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Hooning MJ; Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Hoover RN; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health (NIH), Department of Health and Human Services, Bethesda, MD, USA.
Hopper JL; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.
Howell A; Division of Cancer Sciences, University of Manchester, Manchester, UK.
Huebner H; Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Hulick PJ; Center for Medical Genetics, NorthShore University HealthSystem, Evanston, IL, USA.
Imyanitov EN; N.N. Petrov Institute of Oncology, St. Petersburg, Russia.
Isaacs C; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Izatt L; Clinical Genetics, Guy's and St. Thomas' NHS Foundation Trust, London, UK.
Jager A; Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Jakimovska M; Research Centre for Genetic Engineering and Biotechnology 'Georgi D. Efremov', Macedonian Academy of Sciences and Arts, Skopje, Republic of Macedonia.
Jakubowska A; Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.; Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University, Szczecin, Poland.
James P; Parkville Familial Cancer Centre, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.
Janavicius R; Hematology, Oncology and Transfusion Medicine Center, Department of Molecular and Regenerative Medicine, Vilnius University Hospital Santariskiu Clinics, Vilnius, Lithuania.; State Research Institute Center for Innovative Medicine, Vilnius, Lithuania.
Janni W; Department of Gynaecology and Obstetrics, University Hospital Ulm, Ulm, Germany.
John EM; Department of Medicine, Division of Oncology, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, CA, USA.
Jones ME; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Jung A; Division of Cancer Epidemiology, DKFZ, Heidelberg, Germany.
Kaaks R; Division of Cancer Epidemiology, DKFZ, Heidelberg, Germany.
Kapoor PM; Division of Cancer Epidemiology, DKFZ, Heidelberg, Germany.; Faculty of Medicine, University of Heidelberg, Heidelberg, Germany.
Karlan BY; David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California, Los Angeles, Los Angeles, CA, USA.
Keeman R; Division of Molecular Pathology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Khan S; Department of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
Khusnutdinova E; Institute of Biochemistry and Genetics, Ufa Federal Research Centre of the Russian Academy of Sciences, Ufa, Russia.; Department of Genetics and Fundamental Medicine, Bashkir State Medical University, Ufa, Russia.
Kitahara CM; Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Ko YD; Department of Internal Medicine, Evangelische Kliniken Bonn, Johanniter Krankenhaus, Bonn, Germany.
Konstantopoulou I; Molecular Diagnostics Laboratory, INRASTES, National Centre for Scientific Research 'Demokritos', Athens, Greece.
Koppert LB; Department of Surgical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Koutros S; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health (NIH), Department of Health and Human Services, Bethesda, MD, USA.
Kristensen VN; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Laenkholm AV; Department of Surgical Pathology, Zealand University Hospital, Slagelse, Denmark.
Lambrechts D; VIB Center for Cancer Biology, VIB, Leuven, Belgium.; Laboratory of Translational Genetics, Department of Human Genetics, University of Leuven, Leuven, Belgium.
Larsson SC; Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Laurent-Puig P; Université Paris Sorbonne Cité, INSERM UMR-S1147, Paris, France.
Lazaro C; Molecular Diagnostic Unit, Hereditary Cancer Program, Bellvitge Biomedical Research Institute (IDIBELL), Catalan Institute of Oncology (ICO), CIBERONC, Barcelona, Spain.
Lazarova E; Ss. Cyril and Methodius University in Skopje, Medical Faculty, University Clinic of Radiotherapy and Oncology, Skopje, Republic of North Macedonia.
Lejbkowicz F; Clalit National Cancer Control Center, Carmel Medical Center and Technion Faculty of Medicine, Haifa, Israel.
Leslie G; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Lesueur F; Genetic Epidemiology of Cancer Team, INSERM U900, Paris, France.
Lindblom A; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.; Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden.
Lissowska J; Department of Cancer Epidemiology and Prevention, M. Sklodowska-Curie Cancer Center, Oncology Institute, Warsaw, Poland.
Lo WY; Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.; University of Tübingen, Tübingen, Germany.
Loud JT; Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Lubinski J; Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Lukomska A; Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
MacInnis RJ; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.
Mannermaa A; Translational Cancer Research Area, University of Eastern Finland, Kuopio, Finland.; Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Kuopio, Finland.; Imaging Center, Department of Clinical Pathology, Kuopio University Hospital, Kuopio, Finland.
Manoochehri M; Molecular Genetics of Breast Cancer, DKFZ, Heidelberg, Germany.
Manoukian S; Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy.
Margolin S; Department of Oncology, Södersjukhuset, Stockholm, Sweden.; Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.
Martinez ME; Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.; Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA, USA.
Matricardi L; Immunology and Molecular Oncology Unit, Veneto Institute of Oncology (IOV)-IRCCS, Padua, Italy.
McGuffog L; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
McLean C; Department of Anatomical Pathology, The Alfred Hospital, Melbourne, Victoria, Australia.
Mebirouk N; Genetic Epidemiology of Cancer Team, INSERM U900, Institut Curie, PSL University, Mines ParisTech, Paris, France.
Meindl A; Department of Gynecology and Obstetrics, Ludwig Maximilian University of Munich, Munich, Germany.
Menon U; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
Miller A; NRG Oncology, Statistics and Data Management Center, Roswell Park Cancer Institute, Buffalo, NY, USA.
Mingazheva E; Department of Genetics and Fundamental Medicine, Bashkir State Medical University, Ufa, Russia.
Montagna M; Immunology and Molecular Oncology Unit, Veneto Institute of Oncology (IOV)-IRCCS, Padua, Italy.
Mulligan AM; Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada.; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Mulot C; Université Paris Sorbonne Cité, INSERM UMR-S1147, Paris, France.
Muranen TA; Department of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
Nathanson KL; Department of Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Neuhausen SL; Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA.
Nevanlinna H; Department of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
Neven P; Leuven Multidisciplinary Breast Center, Department of Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
Newman WG; Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester NIHR Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.; Division of Evolution and Genomic Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
Nielsen FC; Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Nikitina-Zake L; Latvian Biomedical Research and Study Centre, Riga, Latvia.
Nodora J; Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.; Department of Family Medicine and Public Health, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
Offit K; Clinical Genetics Research Laboratory, Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Olah E; Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary.
Olopade OI; Center for Clinical Cancer Genetics, The University of Chicago, Chicago, IL, USA.; Department of Clinical Pathology, University of Melbourne, Melbourne, Victoria, Australia.
Olsson H; Department of Cancer Epidemiology, Clinical Sciences, Lund University, Lund, Sweden.; Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Orr N; Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, Northern Ireland, UK.
Papi L; Unit of Medical Genetics, Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy.
Papp J; Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary.
Park-Simon TW; Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
Parsons MT; Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Peissel B; Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy.
Peixoto A; Department of Genetics, Portuguese Oncology Institute, Porto, Portugal.
Peshkin B; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Peterlongo P; Genome Diagnostics Program, IFOM, FIRC Institute of Molecular Oncology, Milan, Italy.
Peto J; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.; Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
Phillips KA; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.; Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
Piedmonte M; NRG Oncology, Statistics and Data Management Center, Roswell Park Cancer Institute, Buffalo, NY, USA.
Plaseska-Karanfilska D; Research Centre for Genetic Engineering and Biotechnology 'Georgi D. Efremov', Macedonian Academy of Sciences and Arts, Skopje, Republic of Macedonia.
Prajzendanc K; Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Prentice R; Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Prokofyeva D; Department of Genetics and Fundamental Medicine, Bashkir State Medical University, Ufa, Russia.
Rack B; Department of Gynaecology and Obstetrics, University Hospital Ulm, Ulm, Germany.
Radice P; Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, INT, Milan, Italy.
Ramus SJ; Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.; School of Women's and Children's Health, Faculty of Medicine, University of NSW Sydney, Sydney, New South Wales, Australia.; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
Rantala J; Clinical Genetics, Karolinska Institutet, Stockholm, Sweden.
Rashid MU; Molecular Genetics of Breast Cancer, DKFZ, Heidelberg, Germany.; Department of Basic Sciences, Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH&RC), Lahore, Pakistan.
Rennert G; Clalit National Cancer Control Center, Carmel Medical Center and Technion Faculty of Medicine, Haifa, Israel.
Rennert HS; Clalit National Cancer Control Center, Carmel Medical Center and Technion Faculty of Medicine, Haifa, Israel.
Risch HA; Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA.
Romero A; Medical Oncology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.; Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal.
Rookus MA; Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Rübner M; Department of Gynaecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center ER-EMN, Erlangen, Germany.
Rüdiger T; Institute of Pathology, Staedtisches Klinikum Karlsruhe, Karlsruhe, Germany.
Saloustros E; Department of Oncology, University Hospital of Larissa, Larissa, Greece.
Sampson S; Prevent Breast Cancer Centre and Nightingale Breast Screening Centre, Manchester University NHS Foundation Trust, Manchester, UK.
Sandler DP; Epidemiology Branch, National Institute of Environmental Health Sciences, NIH, Durham, NC, USA.
Sawyer EJ; Research Oncology, Guy's Hospital, King's College London, London, UK.
Scheuner MT; Cancer Genetics and Prevention Program, University of California, San Francisco, San Francisco, CA, USA.
Schmutzler RK; Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Schneeweiss A; Molecular Biology of Breast Cancer, University Women's Clinic Heidelberg, University of Heidelberg, Heidelberg, Germany.; NCT, University Hospital and DKFZ, Heidelberg, Germany.
Schoemaker MJ; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Schöttker B; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Schürmann P; Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
Senter L; Clinical Cancer Genetics Program, Division of Human Genetics, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Sharma P; Department of Internal Medicine, Division of Oncology, University of Kansas Medical Center, Westwood, Kansas City, KS, USA.
Sherman ME; Department of Health Sciences Research, Mayo Clinic College of Medicine, Jacksonville, FL, USA.
Shu XO; Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
Singer CF; Department of Obstetrics and Gynecology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Smichkoska S; Ss. Cyril and Methodius University in Skopje, Medical Faculty, University Clinic of Radiotherapy and Oncology, Skopje, Republic of North Macedonia.
Soucy P; Genomics Center, Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Québec City, Québec, Canada.
Southey MC; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia.
Spinelli JJ; Population Oncology, BC Cancer, Vancouver, British Columbia, Canada.; School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada.
Stone J; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.; Curtin UWA Centre for Genetic Origins of Health and Disease, Curtin University and University of Western Australia, Perth, Western Australia, Australia.
Stoppa-Lyonnet D; Department of Genetics, INSERM U830, Institut Curie, Paris Descartes Sorbonne-Paris Cité University, Paris, France.
Swerdlow AJ; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.; Division of Breast Cancer Research, The Institute of Cancer Research, London, UK.
Szabo CI; National Human Genome Research Institute, National Cancer Institute, Bethesda, MD, USA.
Tamimi RM; Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Tapper WJ; Faculty of Medicine, University of Southampton, Southampton, UK.
Taylor JA; Epidemiology Branch, National Institute of Environmental Health Sciences, NIH, Durham, NC, USA.; Epigenetic and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, NIH, Durham, NC, USA.
Teixeira MR; Department of Genetics, Portuguese Oncology Institute, Porto, Portugal.; Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal.
Terry M; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
Thomassen M; Department of Clinical Genetics, Odense University Hospital, Odense, Denmark.
Thull DL; Department of Medicine, Magee-Womens Hospital, School of Medicine, University of Pittsburgh , Pittsburgh, PA, USA.
Tischkowitz M; Program in Cancer Genetics, Departments of Human Genetics and Oncology, McGill University, Montréal, Québec, Canada.; Department of Medical Genetics, National Institute for Health Research, Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK.
Toland AE; Department of Cancer Biology and Genetics, The Ohio State University, Columbus, OH, USA.
Tollenaar RAEM; Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands.
Tomlinson I; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.; Wellcome Trust Centre for Human Genetics and Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, UK.
Torres D; Molecular Genetics of Breast Cancer, DKFZ, Heidelberg, Germany.; Institute of Human Genetics, Pontificia Universidad Javeriana, Bogota, Colombia.
Troester MA; Department of Epidemiology, Gillings School of Global Public Health and UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Truong T; Cancer and Environment Group, Center for Research in Epidemiology and Population Health (CESP), INSERM, University Paris-Sud, University of Paris-Saclay, Paris, France.
Tung N; Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Untch M; Department of Gynecology and Obstetrics, Helios Clinics Berlin-Buch, Berlin, Germany.
Vachon CM; Department of Health Science Research, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA.
van den Ouweland AMW; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, the Netherlands.
van der Kolk LE; Family Cancer Clinic, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
van Veen EM; Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester NIHR Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.; Division of Evolution and Genomic Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
vanRensburg EJ; Department of Genetics, University of Pretoria, Pretoria, South Africa.
Vega A; Molecular Medicine Unit, Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain.; Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago, Servicio Galego de Saude (SERGAS), Santiago de Compostela, Spain.; CIBERER, Santiago de Compostela, Spain.
Wappenschmidt B; Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Weinberg CR; Biostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, NIH, Durham, NC, USA.
Weitzel JN; Clinical Cancer Genomics, City of Hope, Duarte, CA, USA.
Wildiers H; Leuven Multidisciplinary Breast Center, Department of Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
Winqvist R; Laboratory of Cancer Genetics and Tumor Biology, Cancer and Translational Medicine Research Unit, Biocenter Oulu, University of Oulu, Oulu, Finland.; Laboratory of Cancer Genetics and Tumor Biology, Northern Finland Laboratory Centre Oulu, Oulu, Finland.; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.; Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.
Wolk A; Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University, Szczecin, Poland.; Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Yang XR; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health (NIH), Department of Health and Human Services, Bethesda, MD, USA.
Yannoukakos D; Molecular Diagnostics Laboratory, INRASTES, National Centre for Scientific Research 'Demokritos', Athens, Greece.
Zheng W; Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
Zorn KK; Magee-Womens Hospital, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Milne RL; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia.
Kraft P; Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Simard J; Genomics Center, Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Québec City, Québec, Canada.
Pharoah PDP; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Michailidou K; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.; Biostatistics Unit, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.; Cyprus School of Molecular Medicine, Nicosia, Cyprus.
Antoniou AC; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Schmidt MK; Division of Molecular Pathology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Chenevix-Trench G; Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Easton DF; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
Chatterjee N; Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. .; Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA. .
García-Closas M; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health (NIH), Department of Health and Human Services, Bethesda, MD, USA.
Pokaż więcej
Corporate Authors :
kConFab Investigators
ABCTB Investigators
EMBRACE Study
GEMO Study Collaborators
Źródło :
Nature genetics [Nat Genet] 2020 Jun; Vol. 52 (6), pp. 572-581. Date of Electronic Publication: 2020 May 18.
Typ publikacji :
Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
Journal Info :
Publisher: Nature Pub. Co Country of Publication: United States NLM ID: 9216904 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-1718 (Electronic) Linking ISSN: 10614036 NLM ISO Abbreviation: Nat. Genet. Subsets: MEDLINE
MeSH Terms :
Genome-Wide Association Study*
Breast Neoplasms/*genetics
BRCA1 Protein/genetics ; Breast Neoplasms/pathology ; Case-Control Studies ; Female ; Genetic Predisposition to Disease ; Humans ; Linkage Disequilibrium ; Mutation ; Triple Negative Breast Neoplasms/genetics ; Triple Negative Breast Neoplasms/pathology
Czasopismo naukowe
Tytuł :
Tissue-resident memory T cells in breast cancer control and immunotherapy responses.
Autorzy :
Byrne A; Division of Research, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.
Savas P; Division of Research, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
Sant S; Division of Research, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
Li R; Division of Research, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.; Department of Surgery, Royal Melbourne Hospital and Royal Women's Hospital, Melbourne, Victoria, Australia.
Virassamy B; Division of Research, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.
Luen SJ; Division of Research, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
Beavis PA; Division of Research, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
Mackay LK; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia.
Neeson PJ; Division of Research, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
Loi S; Division of Research, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia. .; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia. .
Pokaż więcej
Źródło :
Nature reviews. Clinical oncology [Nat Rev Clin Oncol] 2020 Jun; Vol. 17 (6), pp. 341-348. Date of Electronic Publication: 2020 Feb 28.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
Journal Info :
Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101500077 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1759-4782 (Electronic) Linking ISSN: 17594774 NLM ISO Abbreviation: Nat Rev Clin Oncol Subsets: MEDLINE
MeSH Terms :
Breast Neoplasms/*immunology
Immunologic Memory/*immunology
Lymphocytes, Tumor-Infiltrating/*immunology
T-Lymphocytes/*immunology
Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Agents, Immunological/therapeutic use ; Breast Neoplasms/metabolism ; Breast Neoplasms/therapy ; CD8-Positive T-Lymphocytes ; Humans ; Immunologic Surveillance ; Immunotherapy, Adoptive ; Receptor, ErbB-2/metabolism ; T-Lymphocyte Subsets/immunology ; Triple Negative Breast Neoplasms/immunology ; Triple Negative Breast Neoplasms/metabolism ; Triple Negative Breast Neoplasms/therapy
Czasopismo naukowe
Tytuł :
Targeting claudin-4 enhances chemosensitivity in breast cancer.
Autorzy :
Luo Y; Department of Molecular Pathology, Nara Medical University, Nara, Japan.; Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education, Co-Innovation Center of Neuroregeneration, Nantong University, Nantong, Japan.
Kishi S; Department of Molecular Pathology, Nara Medical University, Nara, Japan.
Sasaki T; Department of Molecular Pathology, Nara Medical University, Nara, Japan.
Ohmori H; Department of Molecular Pathology, Nara Medical University, Nara, Japan.
Fujiwara-Tani R; Department of Molecular Pathology, Nara Medical University, Nara, Japan.
Mori S; Department of Molecular Pathology, Nara Medical University, Nara, Japan.
Goto K; Department of Molecular Pathology, Nara Medical University, Nara, Japan.
Nishiguchi Y; Department of Molecular Pathology, Nara Medical University, Nara, Japan.
Mori T; Department of Molecular Pathology, Nara Medical University, Nara, Japan.
Kawahara I; Department of Molecular Pathology, Nara Medical University, Nara, Japan.
Kondoh M; Drug Innovation Center, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Japan.
Kuniyasu H; Department of Molecular Pathology, Nara Medical University, Nara, Japan.
Pokaż więcej
Źródło :
Cancer science [Cancer Sci] 2020 May; Vol. 111 (5), pp. 1840-1850. Date of Electronic Publication: 2020 Mar 18.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Wiley Publishing on behalf of the Japanese Cancer Association Country of Publication: England NLM ID: 101168776 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1349-7006 (Electronic) Linking ISSN: 13479032 NLM ISO Abbreviation: Cancer Sci. Subsets: MEDLINE
MeSH Terms :
Antibodies/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Breast Neoplasms/*drug therapy
Claudin-4/*immunology
Animals ; Antibodies/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Carcinoma, Ductal, Breast/drug therapy ; Carcinoma, Ductal, Breast/metabolism ; Carcinoma, Ductal, Breast/pathology ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Claudin-1 ; Claudin-4/chemistry ; Claudin-4/genetics ; Drug Synergism ; Female ; Humans ; MCF-7 Cells ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Middle Aged ; Paclitaxel/pharmacology ; Paclitaxel/therapeutic use ; Tamoxifen/pharmacology ; Tamoxifen/therapeutic use ; Triple Negative Breast Neoplasms/drug therapy ; Triple Negative Breast Neoplasms/metabolism ; Triple Negative Breast Neoplasms/pathology ; Tumor Microenvironment/drug effects ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant.
Autorzy :
Litton JK; The University of Texas MD Anderson Cancer Center, Houston, TX.
Scoggins ME; The University of Texas MD Anderson Cancer Center, Houston, TX.
Hess KR; The University of Texas MD Anderson Cancer Center, Houston, TX.
Adrada BE; The University of Texas MD Anderson Cancer Center, Houston, TX.
Murthy RK; The University of Texas MD Anderson Cancer Center, Houston, TX.
Damodaran S; The University of Texas MD Anderson Cancer Center, Houston, TX.
DeSnyder SM; The University of Texas MD Anderson Cancer Center, Houston, TX.
Brewster AM; The University of Texas MD Anderson Cancer Center, Houston, TX.
Barcenas CH; The University of Texas MD Anderson Cancer Center, Houston, TX.
Valero V; The University of Texas MD Anderson Cancer Center, Houston, TX.
Whitman GJ; The University of Texas MD Anderson Cancer Center, Houston, TX.
Schwartz-Gomez J; The University of Texas MD Anderson Cancer Center, Houston, TX.
Mittendorf EA; Brigham and Women's Hospital, Boston, MA.
Thompson AM; Baylor College of Medicine, Houston, TX.
Helgason T; The University of Texas MD Anderson Cancer Center, Houston, TX.
Ibrahim N; The University of Texas MD Anderson Cancer Center, Houston, TX.
Piwnica-Worms H; The University of Texas MD Anderson Cancer Center, Houston, TX.
Moulder SL; The University of Texas MD Anderson Cancer Center, Houston, TX.
Arun BK; The University of Texas MD Anderson Cancer Center, Houston, TX.
Pokaż więcej
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Feb 10; Vol. 38 (5), pp. 388-394. Date of Electronic Publication: 2019 Aug 28.
Typ publikacji :
Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info :
Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J. Clin. Oncol. Subsets: MEDLINE
MeSH Terms :
Breast Neoplasms/*drug therapy
Breast Neoplasms/*genetics
Phthalazines/*administration & dosage
Administration, Oral ; Adult ; BRCA1 Protein/genetics ; BRCA2 Protein/genetics ; Breast Neoplasms/surgery ; Chemotherapy, Adjuvant ; Female ; Germ-Line Mutation ; Humans ; Medication Adherence ; Middle Aged ; Neoadjuvant Therapy ; Phthalazines/adverse effects ; Pilot Projects ; Poly(ADP-ribose) Polymerase Inhibitors/administration & dosage ; Poly(ADP-ribose) Polymerase Inhibitors/adverse effects ; Triple Negative Breast Neoplasms/drug therapy ; Triple Negative Breast Neoplasms/genetics
Czasopismo naukowe
Tytuł :
Lower Rate of CTNNB1 Mutations and Higher Rate of APC Mutations in Desmoid Fibromatosis of the Breast: A Series of 134 Tumors.
Autorzy :
Norkowski E; Departments of Pathology.
Masliah-Planchon J; Genetics.
Le Guellec S; Department of Pathology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse.
Trassard M; Departments of Pathology.
Courrèges JB; Department of Pathology, Institut Bergonié, Bordeaux.
Charron-Barra C; Department of Pathology, Centre Georges-François Leclerc, Dijon.
Terrier P; Department of Pathology, Institut Gustave Roussy, Villejuif.
Bonvalot S; Surgery, Institut Curie, PSL Research University, Paris.
Coindre JM; Department of Pathology, Institut Bergonié, Bordeaux.
Laé M; Departments of Pathology.; Department of Pathology, Centre Henri Becquerel, INSERM U1245, UniRouen Normandie Université, Rouen, France.
Pokaż więcej
Źródło :
The American journal of surgical pathology [Am J Surg Pathol] 2020 Sep; Vol. 44 (9), pp. 1266-1273.
Typ publikacji :
Journal Article; Multicenter Study
Journal Info :
Publisher: Wolters Kluwer Health, Inc Country of Publication: United States NLM ID: 7707904 Publication Model: Print Cited Medium: Internet ISSN: 1532-0979 (Electronic) Linking ISSN: 01475185 NLM ISO Abbreviation: Am J Surg Pathol Subsets: MEDLINE
MeSH Terms :
Mutation*
Adenomatous Polyposis Coli Protein/*genetics
Biomarkers, Tumor/*genetics
Breast Neoplasms/*genetics
Breast Neoplasms, Male/*genetics
Fibromatosis, Aggressive/*genetics
beta Catenin/*genetics
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Breast Neoplasms/pathology ; Breast Neoplasms/therapy ; Breast Neoplasms, Male/pathology ; Breast Neoplasms, Male/therapy ; Female ; Fibromatosis, Aggressive/pathology ; Fibromatosis, Aggressive/therapy ; France ; Genetic Predisposition to Disease ; Humans ; Male ; Middle Aged ; Mutation Rate ; Phenotype ; Prognosis ; Young Adult
Czasopismo naukowe
Tytuł :
IL-8 and MCP-1/CCL2 regulate proteolytic activity in triple negative inflammatory breast cancer a mechanism that might be modulated by Src and Erk1/2.
Autorzy :
Mohamed HT; Department of Zoology, Faculty of Science, Cairo University, Giza 12613, Egypt; Faculty of Biotechnology, October University for Modern Sciences and Arts, Giza 12451, Egypt.
El-Ghonaimy EA; Department of Zoology, Faculty of Science, Cairo University, Giza 12613, Egypt.
El-Shinawi M; Department of General Surgery, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt.
Hosney M; Department of Zoology, Faculty of Science, Cairo University, Giza 12613, Egypt.
Götte M; Department of Gynecology and Obstetrics, Münster University Hospital, Münster 48149, Germany.
Woodward WA; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
El-Mamlouk T; Department of Zoology, Faculty of Science, Cairo University, Giza 12613, Egypt.
Mohamed MM; Department of Zoology, Faculty of Science, Cairo University, Giza 12613, Egypt. Electronic address: .
Pokaż więcej
Źródło :
Toxicology and applied pharmacology [Toxicol Appl Pharmacol] 2020 Aug 15; Vol. 401, pp. 115092. Date of Electronic Publication: 2020 Jun 05.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info :
Publisher: Academic Press Country of Publication: United States NLM ID: 0416575 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-0333 (Electronic) Linking ISSN: 0041008X NLM ISO Abbreviation: Toxicol. Appl. Pharmacol. Subsets: MEDLINE
MeSH Terms :
Chemokine CCL2/*biosynthesis
Genes, src/*physiology
Inflammatory Breast Neoplasms/*metabolism
Interleukin-8/*biosynthesis
MAP Kinase Signaling System/*physiology
Triple Negative Breast Neoplasms/*metabolism
Adult ; Aged ; Antineoplastic Agents/pharmacology ; Cell Line, Tumor ; Dasatinib/pharmacology ; Female ; Genes, src/drug effects ; Humans ; Inflammatory Breast Neoplasms/pathology ; MAP Kinase Signaling System/drug effects ; Middle Aged ; Proteolysis/drug effects ; Triple Negative Breast Neoplasms/pathology ; Tumor Microenvironment/drug effects ; Tumor Microenvironment/physiology
Czasopismo naukowe
Tytuł :
An update review of deregulated tumor suppressive microRNAs and their contribution in various molecular subtypes of breast cancer.
Autorzy :
Dastmalchi N; Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Safaralizadeh R; Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran. Electronic address: .
Baradaran B; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Hosseinpourfeizi M; Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran.
Baghbanzadeh A; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Pokaż więcej
Źródło :
Gene [Gene] 2020 Mar 01; Vol. 729, pp. 144301. Date of Electronic Publication: 2019 Dec 26.
Typ publikacji :
Journal Article; Review
Journal Info :
Publisher: Elsevier/North-Holland Country of Publication: Netherlands NLM ID: 7706761 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0038 (Electronic) Linking ISSN: 03781119 NLM ISO Abbreviation: Gene Subsets: MEDLINE
MeSH Terms :
Breast Neoplasms/*genetics
Genes, Tumor Suppressor/*physiology
MicroRNAs/*genetics
Apoptosis/genetics ; Breast Neoplasms/pathology ; Cell Movement/genetics ; Cell Proliferation/genetics ; Female ; Humans ; Neoplasm Metastasis/genetics ; Triple Negative Breast Neoplasms/pathology
Czasopismo naukowe
Tytuł :
Image-based screening for men at high risk for breast cancer: Benefits and drawbacks.
Autorzy :
Woods RW; Department of Radiology, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, Madison, WI 53792, USA. Electronic address: .
Salkowski LR; Department of Radiology, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, Madison, WI 53792, USA; Department of Medical Physics, University of Wisconsin School of Medicine and Public Health, 1111 Highland Avenue, Madison, WI 53705, USA.
Elezaby M; Department of Radiology, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, Madison, WI 53792, USA.
Burnside ES; Department of Radiology, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, Madison, WI 53792, USA.
Strigel RM; Department of Radiology, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, Madison, WI 53792, USA; University of Wisconsin Carbone Cancer Center, 600 Highland Avenue, Madison, WI 53792, USA; Department of Medical Physics, University of Wisconsin School of Medicine and Public Health, 1111 Highland Avenue, Madison, WI 53705, USA.
Fowler AM; Department of Radiology, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, Madison, WI 53792, USA; University of Wisconsin Carbone Cancer Center, 600 Highland Avenue, Madison, WI 53792, USA; Department of Medical Physics, University of Wisconsin School of Medicine and Public Health, 1111 Highland Avenue, Madison, WI 53705, USA.
Pokaż więcej
Źródło :
Clinical imaging [Clin Imaging] 2020 Mar; Vol. 60 (1), pp. 84-89. Date of Electronic Publication: 2019 Nov 28.
Typ publikacji :
Journal Article; Review
Journal Info :
Publisher: Elsevier Country of Publication: United States NLM ID: 8911831 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-4499 (Electronic) Linking ISSN: 08997071 NLM ISO Abbreviation: Clin Imaging Subsets: MEDLINE
MeSH Terms :
Breast Neoplasms, Male/*diagnostic imaging
Adult ; Breast Neoplasms/diagnostic imaging ; Breast Neoplasms/epidemiology ; Breast Neoplasms/pathology ; Breast Neoplasms, Male/epidemiology ; Early Detection of Cancer ; Female ; Humans ; Male ; Mammography ; Mass Screening ; Middle Aged ; Risk Factors
Czasopismo naukowe
Tytuł :
Study of the antitumour effects and the modulation of immune response by histamine in breast cancer.
Autorzy :
Nicoud MB; Laboratory of Tumour Biology and Inflammation, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA), and the National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina.; Laboratory of Radioisotopes, School of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina.
Sterle HA; Neuroimmunomodulation and Molecular Oncology Division, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA), and the National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina.
Massari NA; Immunology Department, School of Natural Sciences, National University of Patagonia San Juan Bosco, Chubut, Argentina.
Táquez Delgado MA; Laboratory of Tumour Biology and Inflammation, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA), and the National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina.
Formoso K; Pharmacology and Function of Ionic Channels Laboratory, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA), and the National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina.
Herrero Ducloux MV; Pathology Department, School of Natural Sciences, National University of Patagonia San Juan Bosco, Chubut, Argentina.
Martinel Lamas D; Laboratory of Tumour Biology and Inflammation, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA), and the National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina.
Cremaschi GA; Neuroimmunomodulation and Molecular Oncology Division, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA), and the National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina.
Medina VA; Laboratory of Tumour Biology and Inflammation, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA), and the National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina. .; Laboratory of Radioisotopes, School of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina. .
Pokaż więcej
Źródło :
British journal of cancer [Br J Cancer] 2020 Feb; Vol. 122 (3), pp. 348-360. Date of Electronic Publication: 2019 Nov 21.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info :
Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE
MeSH Terms :
Apoptosis/*drug effects
Cell Proliferation/*drug effects
Histamine Agonists/*pharmacology
Histamine Antagonists/*pharmacology
Histidine Decarboxylase/*metabolism
Receptors, Histamine H4/*genetics
Receptors, Histamine H4/*metabolism
Triple Negative Breast Neoplasms/*metabolism
Animals ; Breast Neoplasms/metabolism ; Breast Neoplasms/mortality ; Cell Line, Tumor ; Cell Survival/drug effects ; Databases, Factual ; Female ; Histamine/pharmacology ; Humans ; Indoles/pharmacology ; Lymphocytes, Tumor-Infiltrating/drug effects ; Mice ; Mice, Inbred BALB C ; Mice, Knockout ; Oximes/pharmacology ; Piperazines/pharmacology ; Prognosis ; Triple Negative Breast Neoplasms/mortality ; Tumor Burden ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Candidate circulating microRNAs as potential diagnostic and predictive biomarkers for the monitoring of locally advanced breast cancer patients.
Autorzy :
Ibrahim AM; Biochemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt.; Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Said MM; Biochemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt.
Hilal AM; Medical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Medhat AM; Biochemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt.
Abd Elsalam IM; Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Pokaż więcej
Źródło :
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine [Tumour Biol] 2020 Oct; Vol. 42 (10), pp. 1010428320963811.
Typ publikacji :
Journal Article
Journal Info :
Publisher: SAGE Country of Publication: United States NLM ID: 8409922 Publication Model: Print Cited Medium: Internet ISSN: 1423-0380 (Electronic) Linking ISSN: 10104283 NLM ISO Abbreviation: Tumour Biol Subsets: MEDLINE
MeSH Terms :
Biomarkers, Tumor*
Circulating MicroRNA*
MicroRNAs*
Breast Neoplasms/*diagnosis
Breast Neoplasms/*genetics
Adult ; Breast Neoplasms/mortality ; Breast Neoplasms/therapy ; Combined Modality Therapy ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Kaplan-Meier Estimate ; Middle Aged ; Neoplasm Grading ; Neoplasm Metastasis ; Neoplasm Staging ; Prognosis ; Real-Time Polymerase Chain Reaction ; Sensitivity and Specificity
Czasopismo naukowe
Tytuł :
Are we ready to use TMB in breast cancer clinical practice?
Autorzy :
Ravaioli S; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, FC, Italy.
Limarzi F; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, FC, Italy.
Tumedei MM; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, FC, Italy.
Palleschi M; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, FC, Italy.
Maltoni R; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, FC, Italy.
Bravaccini S; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, FC, Italy. .
Pokaż więcej
Źródło :
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2020 Oct; Vol. 69 (10), pp. 1943-1945. Date of Electronic Publication: 2020 Jul 28.
Typ publikacji :
Editorial
Journal Info :
Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE
MeSH Terms :
Molecular Targeted Therapy*
Mutation*
Antineoplastic Agents/*therapeutic use
Biomarkers, Tumor/*genetics
Breast Neoplasms/*drug therapy
Breast Neoplasms/*genetics
Biomarkers, Tumor/antagonists & inhibitors ; Breast Neoplasms/immunology ; Breast Neoplasms/pathology ; DNA Mutational Analysis ; Female ; Humans ; Prognosis
Opinia redakcyjna
Tytuł :
Docosahexaenoic acid (DHA) inhibits pro-angiogenic effects of breast cancer cells via down-regulating cellular and exosomal expression of angiogenic genes and microRNAs.
Autorzy :
Aslan C; Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Maralbashi S; Chronic Kidney Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Kahroba H; Department of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Asadi M; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Soltani-Zangbar MS; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Javadian M; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Shanehbandi D; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Baradaran B; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Darabi M; Biochemistry & Clinical Laboratories, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Kazemi T; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: .
Pokaż więcej
Źródło :
Life sciences [Life Sci] 2020 Oct 01; Vol. 258, pp. 118094. Date of Electronic Publication: 2020 Jul 13.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Elsevier Country of Publication: Netherlands NLM ID: 0375521 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0631 (Electronic) Linking ISSN: 00243205 NLM ISO Abbreviation: Life Sci. Subsets: MEDLINE
MeSH Terms :
Down-Regulation*/drug effects
Down-Regulation*/genetics
Breast Neoplasms/*blood supply
Breast Neoplasms/*genetics
Docosahexaenoic Acids/*pharmacology
Exosomes/*genetics
MicroRNAs/*genetics
Neovascularization, Pathologic/*genetics
Breast Neoplasms/drug therapy ; Breast Neoplasms/ultrastructure ; Cell Line, Tumor ; Exosomes/drug effects ; Exosomes/ultrastructure ; Female ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; MicroRNAs/metabolism
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies